Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Acquires Rights to Lung Cancer Test from Wistar

NEW YORK (GenomeWeb) – OncoCyte announced today that it has signed a deal to acquire the exclusive commercial rights to a blood-based lung cancer diagnostic developed with the Wistar Institute.

OncoCyte and Wistar have been collaborating on the test since 2013. Last year, Wistar researchers presented positive interim clinical data showing that a prototype test measuring the expression of circulating messenger RNA and microRNAs could distinguish patients with malignant lung nodules from those with benign or no nodules with an area under the curve of .88 with sensitivity of 76 percent and specificity of 88 percent.

With the agreement, OncoCyte has obtained the full rights to the technology underlying the test from Wistar. A company spokesperson said OncoCyte is in the process of expanding the number of biomarkers used in the assay, with final clinical validation and a commercial launch expected by year end.

"Our lung cancer test addresses a large unmet need for the estimated 10 million high-risk patients in the US who require annual testing," OncyCyte CEO William Annett said in a statement. "Today's standard of care, LDCT screening, has a high false positive rate, so our lung cancer test is intended to improve patient outcomes and reduce costs to the healthcare system through the early and accurate detection of cancer."

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.